Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Obesity is the single most important factor for the current increase in diabetes. There are different types of obesity: abdominal obesity is linked with diabetes and heart disease. Important genes have been identified. The Oxford Biobank will help us better understand physiology and function, the link between the molecule and the patient.

Q: How does obesity influence diabetes?

FK: At several levels, and obesity is actually the single most important factor for the increase in diabetes we see right now. We all know that people are becoming fatter and fatter, that is something we can see. The way it works is not entirely clear, but we know that obesity increases the demand for insulin secretion, and where the demand is not met, the pancreas doesn't secret enough insulin, there isn't enough insulin around to lower the glucose, and we actually get diabetes.

Q: Are there different types of obesity?

FK: Yes, I think the focus has been very much on abdominal obesity, the male pattern type of obesity, because it is so strongly associated with diabetes and heart disease and a variety of other illnesses as well. It is interesting to note however that there is a female pattern of obesity, that is the lower body fat, and that has the opposite associations; you are actually protected as a woman with big hips. Women don't like to hear that but it is actually the case! The most extreme variant is when adipose tissue doesn't work any longer, and you lose the fat completely, or in parts of the body, and then you get into real trouble metabolically.

Q: I thought that fat was just stored, how can they be so different?

FK: I think that is something we are learning more and more about. It is probably down to the architecture and the origin of the actual fat cells. They seem, when we look at them closely, to be coming from different types of stem cells and have markers with that. I think that in that we have some of the origins of the rather troublesome and difficult conditions that I talked about, the lipodystrophy, when you lose fat. We have actually recently studied one particular patient who underwent surgery, bariatric surgery for obesity, and she lost a phenomenal amount of fat. Her diabetes disappeared after only a couple of weeks. It was a bit of a miracle, and we have actually never done that in such a patient before so that is actually new for Oxford.

Q: What are the most important lines of research that have developed over the last five or ten years?

FK: In this particular area (obesity and the links to diabetes), I think it has become clear over the past years that obesity as such emerges from energy balance that is driven by satiety, and that is governed by central systems; recognition in the brain etc. Whereas the complications of obesity and this is new, arises from things going wrong in the periphery; in the skeletal muscle, adipose tissue, and also the liver.

Q: Why does your line of research matter? Why should we put money into it?

FK: I think it is almost self evident when more than 10% of the entire NHS budget goes to obesity and diabetes and its complications, and it might not be enough to count only 10% because obesity is related to so many other things which cost society a lot of money such as depression, cancer, and other major disease areas.

Q: How does your research fit into translational medicine within the department?

FK: We have benefited a lot from one of Oxford's real strengths, and that's the elucidation of some of the genes underlying complex disorders such as diabetes and obesity. Now is the time to harvest and translate this into the benefit of patients. We are actually funded by the Oxford Biomedical Research Centre to do research along that line. It is not trivial; it is not an easy step to go from molecule to patient. It needs several steps and one of the steps that I believe is quite important is to have a link between the molecule and the patient to understand physiology and function. For that reason we have set up something called the Oxford Biobank where we can go into the population and ask people with certain genetic variants, or certain characteristics to come back and take part in research and help us to understand function before we move into studying patients and liaise with external companies or our own research lines to find new therapies for diabetes and obesity.

Fredrik Karpe

Oxford Biobank

Prof. Fredrik Karpe initiated the Oxford Biobank for prospective genetic epidemiological research. Integrative physiological and genomic approaches are used to study lipid and carbohydrate metabolism. Prof. Karpe also studies the links between obesity, insulin resistance, type 2 diabetes and cardiovascular disease.

This podcast presents the research done by Prof. Karpe whilst working in the Nuffield Department of Medicine. Prof. Fredrik Karpe now works at the Radcliffe Department of Medicine.

More podcasts related to Ex-faculty podcasts

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Richard Antrobus: Universal Flu Vaccine

A Universal Flu Vaccine would protect against a wide range of strains of the virus. Universal vaccines target the parts of the virus that stay relatively stable and are the same between different strains of flu. The ultimate goal is to produce a vaccine that will eventually replace the normal seasonal flu jab.

Colin Baigent: Lowering cholesterol in chronic kidney disease

The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Colin Baigent: Wider statin use saves lives

Prof Colin Baigent discusses how the benefits outweigh the hazards of Cholesterol-lowering drugs.

Paul Bowness: Spondyloarthritis

Spondyloarthritis describes a group of arthritic illnesses where there is inflammation of the joints of the lower back. Joints become painful and stiff, and inflammation ultimately fuses the spine. A better understanding of the role of various immune components might help us better prevent it and perhaps cure it.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Hal Drakesmith: Iron and Infection

Pathogens can escape recognition by the immune system, but they require iron from their host to grow and spread. If iron availability is high, infection can progress more rapidly. Diverting iron away from invading microbes slows their growth, giving time for our immune mechanisms to clear the infection. Manipulating iron transport might lead to new strategies to combat infections.

Christian Eggeling: Nano-immunology

Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. This has the potential to help us design new drugs and developing new ways of treating diseases.

Barbara Fielding: Metabolism of Fatty Acids

Obesity puts a huge strain on health care services in the UK, with 61% of people in England being overweight. By tracing fats containing heavy atoms from meals into the blood, her aim is to learn more about fat metabolism and target treatments for the complications associated with obesity and diabetes.

Alexander Finlayson: MedicineAfrica

This podcast presents the research done by Dr Alexander Finlayson whilst working in the Nuffield Department of Medicine. Dr Finlayson now works at the Nuffield Department of Population Health.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.